Extract

This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.

Inclusion criteria

• Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis

Country

• France
• Germany
• Italy
• United States

Links

• ictrp
• nct